News

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a

Momentum investing is essentially an exception to the idea of "buying low and selling high." Investors following this style of investing are usually not interested in betting on cheap stocks and

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks

CRA International, Inc. CRAI reported impressive first-quarter 2025 results, with earnings and revenues beating the Zacks Consensus Estimate. The stock has barely moved since the earnings release

For Immediate Release

Chicago, IL – May 5, 2025– Today, Zacks Investment Ideas feature highlights Quanta Services PWR, BWX Technologies, Inc. BWXT and Constellation Energy CEG.

Top Nuclear Energy

Carvana CVNA is slated to release first-quarter 2025 results on Wednesday, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings and revenues is pegged at 75

A fresh wave of auto tariffs is rattling the U.S. auto industry — this time targeting imported parts rather than fully assembled vehicles. While previous levies largely spared American-made cars

Henry Schein, Inc. HSIC registered adjusted earnings per share (EPS) of $1.15 in the first quarter of 2025, up 4.5% from the year-ago period’s figure. The figure topped the Zacks Consensus Estimate

Cummins (CMI) came out with quarterly earnings of $5.96 per share, beating the Zacks Consensus Estimate of $4.82 per share. This compares to earnings of $5.10 per share a year ago. These figures are

Tyson Foods (TSN) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.62 per share a year ago. These figures

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and

For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across

How much a stock's price changes over time is important for most investors, since price performance can both impact your investment portfolio and help you compare investment results across sectors

Twist Bioscience (TWST) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to loss of $0.79 per share a year ago. These figures

The three most widely followed indexes in the United States have ended the past trading week on a positive note. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average have gained by

The S&P 500 Index has been able to recoup all losses suffered due to the Trump administration’s tariff-led market mayhem at a lightning speed. On May 2, the broad-market index recorded a nine-day

Wall Street saw severe volatility and almost day-to-day fluctuations in both directions in April. Finally, U.S. stock markets ended mixed last month. The S&P 500 and the Dow fell 3.2% and 0.8%

An updated edition of the March 12, 2025, article.

In the business world, the concept of a wide moat refers to companies with strong, durable competitive advantages that protect them from rivals

BioCryst Pharmaceuticals (BCRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.17 per share a year ago. These

It is not surprising that before an earnings season, every investor looks for stocks that can beat market expectations. This is because investors always try to position themselves ahead of time and